URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Jeff Knight Biography and Net Worth

COO of Crinetics Pharmaceuticals

Jeff Knight joined Crinetics as Chief Operating Officer in 2021. Prior to joining Crinetics, he was responsible for portfolio management and strategy, alliance management, quality and compliance, and corporate operations at Poseida Therapeutics, where he was a member of the executive leadership team. Between 2012 and 2018, Mr. Knight held various positions of increasing responsibility in clinical, development and corporate operations, and program and portfolio management at Amgen, Onyx Pharmaceuticals (a subsidiary of Amgen), and Halozyme Therapeutics. Earlier in his career, he gained valuable clinical development, program management, and regulatory affairs experience at Genentech, Hoechst Marion Roussel (now Sanofi), and PRA International. Mr. Knight earned a Bachelor of Science in nursing from the University of Kansas and a Bachelor of Arts in psychology followed by a Master of Public Health in biostatistics and epidemiology from the University of Oklahoma.

What is Jeff E. Knight's net worth?: The estimated net worth of Jeff E. Knight is at least $2.77 million as of November 22nd, 2024. Mr. Knight owns 51,653 shares of Crinetics Pharmaceuticals stock worth more than $2,768,601 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Knight may own. Additionally, Mr. Knight receives an annual salary of $657,310.00 as COO at Crinetics Pharmaceuticals. Learn More about Jeff E. Knight's net worth.
How old is Jeff E. Knight?: Mr. Knight is currently 53 years old. There are 5 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who is 61 years old. Learn More on Jeff E. Knight's age.
What is Jeff E. Knight's salary?: As the COO of Crinetics Pharmaceuticals, Inc., Mr. Knight earns $657,310.00 per year. There are 2 executives that earn more than Mr. Knight. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on Jeff E. Knight's salary.
How do I contact Jeff E. Knight?: The corporate mailing address for Mr. Knight and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Jeff E. Knight's contact information.
Has Jeff E. Knight been buying or selling shares of Crinetics Pharmaceuticals?: During the last quarter, Jeff E. Knight has sold $28,316.52 in shares of Crinetics Pharmaceuticals stock. Most recently, Jeff E. Knight sold 501 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.52, for a transaction totalling $28,316.52. Following the completion of the sale, the chief operating officer now directly owns 51,653 shares of the company's stock, valued at $2,919,427.56. Learn More on Jeff E. Knight's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 33 times. They sold a total of 554,549 shares worth more than $26,112,214.05. The most recent insider tranaction occured on November, 22nd when COO Jeff E Knight sold 501 shares worth more than $28,316.52. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 11/22/2024.

Jeff E. Knight Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/22/2024	Sell	501	$56.52	$28,316.52	51,653
7/15/2024	Sell	27,000	$55.00	$1,485,000.00	51,653
6/26/2024	Sell	956	$44.38	$42,427.28	52,580
3/22/2024	Sell	32,359	$44.31	$1,433,827.29	52,580
7/26/2022	Sell	1,152	$20.70	$23,846.40	4,950

Jeff E. Knight Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $53.60

$51.73

$54.25

50 Day Range

MA: $57.04

$52.09

$60.69

2 Week Range

Now: $53.60

$33.67

$62.53

Volume

1,940,449 shs

Average Volume

780,930 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now

Jeff Knight Biography and Net Worth

What is Jeff E. Knight's net worth?

How old is Jeff E. Knight?

What is Jeff E. Knight's salary?

How do I contact Jeff E. Knight?

Has Jeff E. Knight been buying or selling shares of Crinetics Pharmaceuticals?

Who are Crinetics Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Crinetics Pharmaceuticals?